Table 2 Comparison between non-BRCA1/2 tumors and a group of sporadic breast carcinomas of the number (and percentage in parenthesis) of positive cases for each immunohistochemical marker, unless otherwise indicated

From: Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families

 

Non-BRCA1/2 (n=50) (%)

P

Sporadic (n=50) (%)

Grade

 1

24 (54.5)

 

10 (20.0)

 2

9 (20.5)

 

17 (34.0)

 3

11 (25.0)

0.002 a

23 (46.0)

Ki-67

 0–5%

35 (70.0)

 

26 (53.1)

 6–25%

9 (18.0)

 

18 (36.7)

 >25%

6 (12.0)

0.1

5 (10.2)

ER

30 (60.0)

0.3

33 (68.8)

PR

28 (56.0)

0.8

27 (55.1)

BCL2

23 (46.0)

0.8

22 (45.8)

p53

7 (14.0)

0.041 a

15 (31.3)

HER-2 (3+)

8 (17.8)

0.9

9 (18.4)

Cyclin D1

28 (56.0)

0.9

28 (56.8)

Cyclin D3

18 (38.3)

0.1

26 (52.0)

Cyclin E

11 (22.0)

0.6

9 (18.0)

Cyclin A

20 (40.0)

0.4

23 (46.9)

Cyclin B1

9 (19.6)

0.3

6 (12.2)

p16

29 (67.4)

0.8

34 (69.4)

p21

18 (36.7)

0.042 a

9 (18.4)

p27

27 (55.1)

0.1

34 (69.4)

Skp2

23 (46.9)

0.7

22 (44.0)

Rb

33 (68.8)

0.1

41 (82.0)

E2F6

17 (34.0)

0.8

17 (34.0)

CHEK2

9 (22.5)

0.6

12 (27.3)

Topo IIα

20 (41.7)

0.8

22 (44.0)

MDM2

7 (14.6)

0.8

8 (16.0)

CK5/6

3 (6.0)

0.1

7 (14.9)

CK8

39 (79.6)

0.8

38 (77.6)

Vimentin

8 (17.0)

0.3

12 (25.5)

Survivin

13 (28.9)

0.5

16 (34.8)

EGFR

6 (14.0)

0.8

7 (14.9)

  1. ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2; EGFR, epidermal growth factor receptor.
  2. Unadjusted P-value for the comparison between non-BRCA1/2 and sporadic tumors.
  3. aAfter corrections for multiple comparisons only the association with grade remained significant (P<0.04).
Back to article page